TABLE 2.
Results of a Multivariate Linear Regression, Including All Control Variables and Parkinson’s Disease Medication Usea
| Proportion of Patients Taking | B | Standard Error | β | p | |
|---|---|---|---|---|---|
| Constant | — | 1.08 | 4.86 | — | NS |
| Age, years | — | 0.10 | 0.05 | 0.14 | 0.047 |
| Female sex | — | 2.30 | 1.01 | −0.16 | 0.024 |
| Education, years | — | 0.23 | 0.16 | −0.10 | NS |
| Disease duration, months | — | 0.00 | 0.01 | 0.01 | NS |
| Beck Depression Inventory | — | 3.279 | 0.41 | 0.57 | <0.001 |
| Carbidopa/Levodopa | 82% | 0.05 | 0.04 | 0.09 | NS |
| Dopamine agonistsb | 44% | 1.14 | 0.93 | −0.08 | NS |
| Amantadine | 16% | 1.00 | 1.28 | 0.05 | NS |
| Selegiline/Rasagiline | 21% | 2.59 | 1.19 | −0.15 | 0.032 |
| Memantine | 3% | 3.06 | 2.73 | −0.07 | NS |
| Entacapone | 20% | 0.62 | 1.18 | 0.04 | NS |
R2=0.45 (p<0.001); N=143.
Pramipexole, ropirinole, rotigotine.